Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Fleshner

Showing results (161-170 of 292) with videos related to

Pageof 30
Sort By:
Epigenomics|July 12, 2022
A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancerMadonna R Peter, Misha Bilenky, Yuliang Shi, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 11, 2014
Health-related quality of life following radical prostatectomy: long-term outcomesAndrew G Matthew, Shabbir M H Alibhai, Tal Davidson, et al.
European Urology Focus|September 11, 2023
Limitations of Prostate Biopsy in Detection of Cribriform and Intraductal Prostate CancerRui M Bernardino, Rashid K Sayyid, Katherine Lajkosz, et al.
International Journal of Cancer|January 6, 2011
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progressionLiyang Liu, Ken J Kron, Vaijayanti V Pethe, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 10, 2010
DNA methylation of HOXD3 as a marker of prostate cancer progressionKen J Kron, Liyang Liu, Vaijayanti V Pethe, et al.
The Journal of Urology|August 23, 2016
Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active SurveillanceFang Zhao, Ekaterina Olkhov-Mitsel, Theodorus van der Kwast, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 27, 2022
Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologistsDouglas C Cheung, Lisa J Martin, Shabbir M H Alibhai, et al.
BJU International|July 18, 2023
Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysisRashid K Sayyid, Zachary Klaassen, Alejandro Berlin, et al.
Urology|November 10, 2019
Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter AnalysisJoon Yau Leong, Jaime O Herrera-Caceres, Hanan Goldberg, et al.
Urologic Oncology|June 23, 2015
The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladderMadhur Nayan, Bimal Bhindi, Julie L Yu, et al.
Pageof 30

Showing results (161-170 of 292) with videos related to

Sort By:
Pageof 30
Epigenomics|July 12, 2022
A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancerMadonna R Peter, Misha Bilenky, Yuliang Shi, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 11, 2014
Health-related quality of life following radical prostatectomy: long-term outcomesAndrew G Matthew, Shabbir M H Alibhai, Tal Davidson, et al.
European Urology Focus|September 11, 2023
Limitations of Prostate Biopsy in Detection of Cribriform and Intraductal Prostate CancerRui M Bernardino, Rashid K Sayyid, Katherine Lajkosz, et al.
International Journal of Cancer|January 6, 2011
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progressionLiyang Liu, Ken J Kron, Vaijayanti V Pethe, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 10, 2010
DNA methylation of HOXD3 as a marker of prostate cancer progressionKen J Kron, Liyang Liu, Vaijayanti V Pethe, et al.
The Journal of Urology|August 23, 2016
Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active SurveillanceFang Zhao, Ekaterina Olkhov-Mitsel, Theodorus van der Kwast, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 27, 2022
Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologistsDouglas C Cheung, Lisa J Martin, Shabbir M H Alibhai, et al.
BJU International|July 18, 2023
Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysisRashid K Sayyid, Zachary Klaassen, Alejandro Berlin, et al.
Urology|November 10, 2019
Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter AnalysisJoon Yau Leong, Jaime O Herrera-Caceres, Hanan Goldberg, et al.
Urologic Oncology|June 23, 2015
The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladderMadhur Nayan, Bimal Bhindi, Julie L Yu, et al.
Pageof 30